# A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

> **NCT02477020** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 164 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** TAK-063 20 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02477020
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-01
- **Primary completion:** 2016-07-13
- **Final completion:** 2016-07-27
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02477020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02477020, "A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT02477020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*